A REVIEW ON MUCORMYCOSIS AND AYUSH GUIDELINES FOR ITS MANAGEMENT
Abstract
Background: Mucormycosis is a fungal infection caused by class Zygomycetes.The infection is common in immunocompromised individuals and in patients with diabetes mellitus, hematological malignancy, solid organ transplants and corticosteroid therapy. The aim of this study is to do a short review on mucormycosis and also focuses on the cause of mucormycosis in COVID 19 along with the Homoeopathic guidelines put forward by AYUSH on its management.
Methods: A review is conducted on the available literature on Mucormycosis to know about the incidence, causative agents, pathogenesis, clinical forms, diagnosis and the guidelines of AYUSH for its management
Conclusion: Mucormycosis is an opportunistic infection in COVID 19 mostly affecting the patients suffering from uncontrolled Diabetes Mellitus and those who are under steroid therapy.
References
Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. Journal of Fungi. 2019 Mar;5(1):26.
Hassan MI, Voigt K. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Medical mycology. 2019 Apr 1;57(Supplement_2):S245-56.
Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021 Mar;9(3):523.
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. Journal of Fungi. 2020 Dec;6(4):265.
Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. Current opinion in infectious diseases. 2013 Dec;26(6):508.
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, Chen SA. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clinical Microbiology and Infection. 2019 Jan 1;25(1):26-34.
Binder U, Maurer E, Lass‐Flörl C. Mucormycosis–from the pathogens to the disease. Clinical Microbiology and Infection. 2014 Jun;20:60-6.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clinical Infectious Diseases. 2012 Feb 1;54(suppl_1):S23-34.
Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clinical microbiology reviews. 2005 Jul;18(3):556-69.
Bouza E, Munoz P, Guinea J. Mucormycosis: an emerging disease?. Clinical Microbiology and Infection. 2006 Dec;12:7-23.
Millon L, Scherer E, Rocchi S, Bellanger AP. Molecular strategies to diagnose mucormycosis. Journal of Fungi. 2019 Mar;5(1):24.
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021 May 21.
Information for Homoeopathy Practitioners for Symptomatic Management of Suspected and Diagnosed cases of Mucormycosis. Government of India, Ministry of Ayush, Drug Policy Section;available at https://www.ayush.gov.in
